Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

clipboard-pencil

About the study

The purpose of this study is to assess the safety, efficacy, and durability of up to two REACT injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with T1DM or T2DM and CKD.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Male or female aged 30 to 80 years, inclusive, on the date informed consent is signed.
  2. Clinical diagnosis of T1DM or T2DM, controlled per institutional standard of care.
  3. The subject has a clinical diagnosis of diabetic nephropathy as the underlying cause of renal disease (diagnosis does not have to be confirmed via renal biopsy).
  4. The subject has a serum glycosylated hemoglobin (HbA1c) level less than 10% at the Screening Visit.
  5. The subject has a documented clinical diagnosis of an eGFR between 20 and 50 mL/min/1.73m² inclusive not requiring renal dialysis.

EXCLUSION CRITERIA

Exclusion Criteria:


The subject has a history of renal transplantation.


The subject has a mean systolic blood pressure greater than or equal to 140 mmHg and/or mean diastolic blood pressure greater than or equal to 90 mmHg at screening.


Subjects with blood pressure outside of this range prior to biopsy/injection may continue if approved by the Medical Monitor.


The subject has hemoglobin levels less than 10 g/dL and is not responsive to the standard medical intervention for CKD-related anemia prior to randomization.


pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition
Chronic Kidney Diseases,Type 1 Diabetes Mellitus,Type 2 Diabetes Mellitus
Age (in years)
30 - 80
Phase
Phase 2
Participants needed
53
Est. Completion Date
May 20, 2025
Treatment type
Interventional

Sponsor
Prokidney
ClinicalTrials.gov identifier
NCT05018416
Study number
REGEN-007

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.